학술논문

Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
Document Type
Journal
Source
EUROPEAN JOURNAL OF CANCER; APR 2018, 92 pS3-pS3, 1p. Supplement: 3
Subject
Language
English
ISSN
18790852